BLUEPRINT MEDICINES: Submits Supplemental New Drug Application to FDA for AYVAKIT™ (avapritinib) for the Treatment of Advanced Systemic Mastocytosis
Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced the submission of a supplemental new drug application (sNDA) to the U.S. Food and Drug Administration (FDA) for AYVAKIT™ (avapritinib) for the treatment of adult patients with advanced systemic mastocytosis (SM).